Cargando…

Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies

OBJECTIVE: The aim of the study was to evaluate the effect of empagliflozin on diffuse myocardial fibrosis by cardiac magnetic resonance (CMR) T1 mapping. RESEARCH METHODS AND PROCEDURES: Databases including PubMed, Cochrane library, Embase, and Sinomed for clinical studies of empagliflozin on myoca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haipeng, Ding, Lin, Tian, Liwen, Tian, Yutian, Liao, Lin, Zhao, Junyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404239/ https://www.ncbi.nlm.nih.gov/pubmed/36034443 http://dx.doi.org/10.3389/fendo.2022.917761

Ejemplares similares

Abnormal Glucose Metabolism Parameters and the Aggressiveness of Differentiated Thyroid Carcinoma: A Hospital-Based Cross-Section Study in China
por: Zhao, Junyu, et al.
Publicado: (2022)

Thyroid diseases are associated with coronavirus disease 2019 infection
por: Tian, Yutian, et al.
Publicado: (2022)

The association between serum selenium levels and pathological features of papillary thyroid cancer in 284 patients
por: Ge, Shenghui, et al.
Publicado: (2023)

Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantification
por: Ntusi, Ntobeko AB, et al.
Publicado: (2014)

Non-invasive measurement of myocardial extracellular volume using T1 mapping as a novel biomarker of diffuse fibrosis in dilated cardiomyopathy
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients
por: Zhou, Fangli, et al.
Publicado: (2021)

Extracellular volume assessed by CMR T1-mapping correlates with histologically determined amount of diffuse fibrosis in DCM
por: aus dem Siepen, Fabian, et al.
Publicado: (2014)

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Hsu, Jung-Chi, et al.
Publicado: (2019)

Systolic T1 mapping for estimation of myocardial diffuse fibrosis
por: Vassiliou, Vassilis, et al.
Publicado: (2016)

Measurement of extracellular volume fraction by cardiac magnetic resonance imaging detects diffuse myocardial fibrosis in systemic sclerosis
por: Lee, Daniel C, et al.
Publicado: (2012)

Dynamic changes in cardiac morphology, function, and diffuse myocardial fibrosis duration of diabetes in type 1 and type 2 diabetic mice models using 7.0 T CMR and echocardiography
por: Zhang, Hong-Kai, et al.
Publicado: (2023)

Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats
por: Lv, Qiuyue, et al.
Publicado: (2020)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

MR extracellular volume mapping and non-contrast T1ρ mapping allow early detection of myocardial fibrosis in diabetic monkeys
por: Zhang, Yu, et al.
Publicado: (2019)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

Myocardial extracellular volume imaging by CMR quantitatively characterizes myocardial infarction and subclinical myocardial fibrosis
por: Ugander, Martin, et al.
Publicado: (2011)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

Myocardial T1 and extracellular volume fraction mapping at 3 tesla
por: Lee, Jason J, et al.
Publicado: (2011)

Myocardial extracellular volume fraction and myocardial fibrosis by cmr in patients with severe aortic stenosis
por: Liberato, Gabriela, et al.
Publicado: (2015)

SAT-540 Primary Aldosteronism Represents Earlier Myocardial Fibrosis Than Essential Hypertension by T1 Mapping
por: Wu, Tao, et al.
Publicado: (2020)

Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats
por: Dana, Parisa, et al.
Publicado: (2022)

Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy
por: Cheng, Yanan, et al.
Publicado: (2023)

The Use of Empagliflozin Post Myocardial Infarction
por: Ravendran, Kapilraj, et al.
Publicado: (2023)

ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial
por: Brandt-Jacobsen, Niels, et al.
Publicado: (2022)

Role of cardiac T1 mapping and extracellular volume in the assessment of myocardial infarction
por: Garg, Pankaj, et al.
Publicado: (2018)

Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
por: Ye, Tongtong, et al.
Publicado: (2022)

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)
por: Jürgens, Mikkel, et al.
Publicado: (2019)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
por: Daud, Elias, et al.
Publicado: (2021)

Identification of myocardial diffuse fibrosis by 11 heartbeat MOLLI T(1) mapping: averaging to improve precision and correlation with collagen volume fraction
por: Vassiliou, Vassilios S., et al.
Publicado: (2017)

ODP404 Effects of Empagliflozin on Serum Androgens Levels in Men Without Diabetes
por: Kosinski, Christophe, et al.
Publicado: (2022)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

Empagliflozin in acute myocardial infarction: the EMMY trial( )
por: von Lewinski, Dirk, et al.
Publicado: (2022)

Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis
por: Wan Azman, Siti Sanaa, et al.
Publicado: (2022)

Myocardial T1 mapping and extracellular volume quantification: an overview of technical and biological confounders
por: Piechnik, Stefan K., et al.
Publicado: (2017)

Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T
por: de Meester de Ravenstein, Christophe, et al.
Publicado: (2015)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
por: Quagliariello, Vincenzo, et al.
Publicado: (2021)

Sample size calculation for clinical trials using cardiac magnetic resonance partition coefficient and extracellular volume fraction for the assessment of diffuse myocardial fibrosis
por: Liu, Songtao, et al.
Publicado: (2013)

The clinical characteristics and gene mutations associated with thyroid hormone resistance syndrome coexisting with pituitary tumors
por: Zhao, Junyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q4pdt70lmjf9ch3i1t82q3pj0n